Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...
GlobalData on MSN1d
Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...
Buy Rating Affirmed: Gilead’s Breakthrough HIV Prevention and Promising Long-Acting Treatments
Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
Inquirer on MSN6d
Gilead licenses HIV-prevention drug to generic drugmakers
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell ...
FiercePharma2d
In long-acting HIV PrEP access showdown with Gilead, GSK moves to triple Apretude supply for certain countries
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...
Star Observer2d
This Breakthrough Twice-Yearly Injection Shows 96% Efficacy Against HIV
Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...
Gilead's tie up with generic cos may not address HIV challenge
Gilead's partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too ...
manilatimes on MSN6d
Gilead licenses anti-HIV drug to generic drugmakers
United States pharmaceutical giant Gilead said on Wednesday it had signed licensing deals with six generic drugmakers to ...
BioSpace6d
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
HIV prevention therapy likely to become cheaper but accessibility concerns remain
Gilead Sciences collaborates with Indian companies to produce affordable generic versions of its HIV prevention therapy, ...